CSL (ASX:CSL) logged $6.43 in underlying NPATA earnings per share for fiscal 2026, compared with $6.65 a year ago, a Tuesday filing showed.
Analysts polled by FactSet expected $6.27.
For the 12 months ended June 30, revenue was $15.8 billion versus $15.56 billion previously, the Australia-listed biotechnology company added. Analysts surveyed by FactSet expected $15.38 billion.
The company's board declared a final dividend of $1.62 per share, unchanged from a year earlier, payable Oct. 2 to shareholders of record as of Sept. 10.
CSL said it expects fiscal 2027 revenue to be in line with fiscal 2026, and underlying net profit after tax growth of about 5%.